Clinical Trial

Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
In this study, the investigators are hypothesizing that daratumumab-hyaluronidase will effectively treat T-ALL in patients who have persistent or recurrent MRD following treatment with chemotherapy.
Protocol Amendment History 16 amendments
This ClinicalTrials.gov record has been amended 16 times since 2022-03-11; most recent amendment 2026-07-16.
Status change: Not Yet Recruiting → Recruiting 2022-06-17
Trial Details
NCT Number NCT05289687
Lead Sponsor Eastern Cooperative Oncology Group
Collaborators: Janssen, LP
Conditions T-cell Acute Lymphoblastic Leukemia
Enrollment 20 participants
Start Date 2023-05-25
Primary Completion 2027-06-30 (estimated)
Study Completion 2027-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-17